NV-5138 C AR Degrader-4 TFA InChi: InChI=1S/C22H19FN4O2/c23-18-8-9-19(24)20(12-18)27-22(29)17-6-3-16(4-7-17)14-26-21(28)10-5-15-2-1-11-25-13-15/h1-13H

InChi: InChI=1S/C22H19FN4O2/c23-18-8-9-19(24)20(12-18)27-22(29)17-6-3-16(4-7-17)14-26-21(28)10-5-15-2-1-11-25-13-15/h1-13H

Smiles: CN1CCN(CC1)C1=CC(NC2=NC3C4=C(CCC=3C=N2)C(=NN4CCO)C(N)=O)=C(C=C1)OC(F)(F)F

Drummond J

19)20)22-23(14)12-5-7-13(8-6-12)26(21

Smiles: CC1=CC=C(C=C1NC1=CC2NC(=O)/C(=C\C3=CC=CN3)/C=2C=C1)NC(=O)NC1=CC(=CC=C1F)C(F)(F)F

NV-5138 C AR Degrader-4 TFA InChi: InChI=1S/C22H19FN4O2/c23-18-8-9-19(24)20(12-18)27-22(29)17-6-3-16(4-7-17)14-26-21(28)10-5-15-2-1-11-25-13-15/h1-13HNV 5138 is an orally and centrally active small molecule drug for the treatment of major depressive disorder (MDD). It directly and selectively activates the mammalian target of rapamycin complex 1 (mTORC1) signaling pathway by binding to and modulating sestrin2, a leucine amino acid sensor and upstream regulatory pathway. The mTORC1 pathway is the same signaling pathway that the NMDA receptor antagonist ketamine activates in the medial prefrontal